What is Seaport Therapeutics 's additional paid-in capital?

Seaport Therapeutics (SPTX) reported additional paid-in capital of $23.83M in Q1 2026.

What does additional paid-in capital mean?

Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.

Seaport Therapeutics SPTX Additional Paid-In Capital

Additional Paid-In Capital at other companies

MYR GroupMYRG

$162.37M+6.2%

NNN REITNNN

$5.3B+1.9%

Piper SandlerPIPR

$1B+1.7%

RepligenRGEN

$1.65B+2.2%

White Mountains Insurance GroupWTM

$578.8M+2.5%

CNX ResourcesCNX

$2.36B+1.4%

Other financials

Income statement

See full

Operating income-$27.5M-70.2%

Net income-$25.4M-93.6%

EPS (diluted)-$10.34-83.0%

Balance sheet

See full

Cash & equivalents$52.9M—

Total debt$5.3M—

Total equity-$115.6M-220%

Total assets$227.7M—

Cash flow

See full

Operating cash flow-$20.2M+0.2%

CapEx--100%

Free cash flow-$20.2M+0.4%

Valuation

See full

Market cap$972.65M—

Enterprise value$925.08M—

Returns & leverage

See full

Debt / equity-0×—

Current ratio13.2×—

Where this comes from

Reported directly by Seaport Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Seaport Therapeutics ’s 10-Q, filed June 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Seaport Therapeutics 's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Seaport Therapeutics 's additional paid-in capital?: Seaport Therapeutics (SPTX) reported additional paid-in capital of $23.83M in Q1 2026.
What does additional paid-in capital mean?: Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.